Estimation of peginesatide utilization requires patient-level data
Post hoc analysis of two Phase 3 pivotal trials (EMERALD 1,2) of peginesatide vs epoetin for anemia due to chronic kidney disease in hemodialysis patients on stable epoetin showed that for increasing doses of baseline epoetin, relatively less peginesatide was needed to achieve similar Hb levels (Fis...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Nephrology
2012-06-01
|
| Series: | Kidney Research and Clinical Practice |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211913212006638 |